Currently Viewing:
Newsroom
Currently Reading
Blood Clots in MPN Related to Higher Cost, Length of Stay for Patients With MPN
August 17, 2019 – AJMC Staff
FDA Panel Backs Use of Descovy for HIV Prevention in Men, Transgender Women
August 16, 2019 – Jaime Rosenberg
Researcher Excited About Future of Psoriasis Treatment
August 16, 2019 – Allison Inserro
This Week in Managed Care: August 16, 2019
August 16, 2019
AJMC® in the Press, August 16, 2019
August 16, 2019 – AJMC Staff
Pediatric Leukemia Treatment Linked to Increased Risk of Infections, Study Finds
August 16, 2019 – Alison Rodriguez
5 Findings From the August 2019 Issue of AJMC®
August 16, 2019 – Christina Mattina
Treatment for Parental Tobacco Use Shown to Be Significantly Effective in a Pediatric Setting, Study Shows
August 16, 2019 – Matthew Gavidia
What We're Reading: Generic Pricing Probe; EpiPen Coverage; Mass. Insurers to Merge
August 16, 2019 – AJMC Staff

What We're Reading: Missouri Abortion Clinic to Stay Open; Red Flags for Esketamine; Opioid Maker Files for Bankruptcy

AJMC Staff
Missouri's only abortion clinic will stay open after a state circuit court judge issued a preliminary injunction; the FDA overlooked red flags for esketamine after Janssen provided only limited data about the drug's safety and efficacy; opiod manufacturer Insys has filed for bankruptcy proctection after agreeing to pay $225 million to settle a federal investigation over its marketing of fentanyl. 

Missouri’s Only Abortion Clinic to Stay Open After Judge Issued an Injunction

State Circuit Court Judge Michael Stelzer issued a preliminary injunction yesterday that will temporarily prevent state officials from shutting down the only abortion clinic in Missouri, The New York Times reported. The clinic’s license wasn’t renewed after officials said that an audit had revealed serious health concerns; with the audit pending, the licene could not be renewed. Stelzer said the state’s Department of Health and Senior Services has until June 21 to make a decision over the license, but that the injunction would remain in effect until he issues another ruling.



FDA Overlooked Red Flags for Esketamine Testing

The FDA approved esketamine as a treatment for intractable depression after Janssen, the drug’s manufacturer, provided only modest evidence it worked from limited trials, Kaiser Health News reported. The company also provided no safety information about eskatamine beyond a period of 60 weeks. Janssen and the FDA dismissed red flags raised during clinical trials when 3 patients in the clinical program died by suicide.



Opioid Manufacturer Insys Files for Bankruptcy

Opioid manufacturer Insys Therapeutics filed for bankruptcy protection yesterday after agreeing to pay $225 million to settle a federal investigation into its marketing practices for fentanyl, according to The New York Times. The company was accused of bribing physicians to prescribe its powerful painkiller and misleading insurers about patients’ need for the drug. Insys said it will continue operating while it creates a plan to pay its creditors under Chapter 11 of the federal bankruptcy code.

Related Articles

Fentanyl Driving Overdose Deaths in the US, CDC Says
Study Criticizes FDA Safety Oversight of Rapid-Release Fentanyl
FDA Approves Esketamine for Treatment-Resistant Depression, First New Type of Antidepressant in 30 Years
What We're Reading: Alabama Abortion Ban; Pennsylvania AG Sues Purdue Pharma; Death Penalty Drug Regulation
What We're Reading: Judge Blocks Mississippi Abortion Law; Oklahoma Opioid Suit; Maine Vaccine Exemption Removal
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up